Table of Contents
Key Points:
- Lamia Tazi, CEO of Sothema, has seen her stake’s market value increase from $59.57 million to $62.6 million due to a share price surge.
- Sothema’s share price on the Casablanca Bourse rose 5.08% in 28 days, pushing its market cap close to $750 million.
- Year-to-date, Sothema has delivered an 8.3% return to investors, reflecting strong confidence in its strategic direction.
Lamia Tazi, CEO of Marocaine Ste de Therapeutique (Sothema) and a top figure in the Moroccan pharmaceutical industry, has recorded a significant increase in the market value of her stake in the healthcare group, thanks to a recent surge in Sothema’s share price on the Casablanca Bourse.
According to data tracked by Billionaires.Africa, Tazi’s stake in Sothema has declined by MAD30.13 million ($3.03 million) over the past 28 days. This follows a period of decline between April 22 and May 1, during which her stake slumped by $2.32 million, from MAD601.15 million ($59.44 million) to MAD577.98 million ($57.12 million).
Sothema’s market cap nears $750 million
Sothema, Morocco’s dominant healthcare company, manufactures roughly 60 million pharmaceutical units annually. The company boasts a diversified portfolio, partnering with 35 multinational laboratories. It exports products across Europe, the Maghreb, Sub-Saharan Africa, and the Persian Gulf, highlighting its role in the regional healthcare supply chain.
Sothema’s share price on the Casablanca bourse has witnessed a 5.08 percent increase over the past 28 days. The price rose from MAD980.2 ($98.45) on May 1 to MAD1,030 ($103.46) at the time of reporting. This surge pushes Sothema’s market capitalization closer to the $750 million mark, delivering significant shareholder value.
Lamia Tazi’s growing wealth
As CEO and chairperson, Tazi holds an 8.4 percent stake in Sothema. With the recent surge in Sothema’s share price, the market value of Tazi’s stake has increased from MAD593.05 million ($59.57 million) on May 1 to MAD623.18 million ($62.6 million), solidifying her position as one of the wealthiest investors on the Casablanca Bourse.
This underscores Lamia Tazi’s leadership and strategic vision in steering Sothema to new heights in the competitive pharmaceutical industry. As Sothema continues to expand its market presence and operational capabilities, stakeholders remain optimistic about its future growth prospects.
Your Money and Your Life
Sothema has been one of the standout performers in the Moroccan market, delivering an 8.31 percent year-to-date return to its investors.
This gain reflects strong investor confidence in the company’s strategic direction and operational performance.
A $100,000 investment in Sothema at the beginning of the year would now be valued at $108,310, representing a gain of $8,310.
